Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 40.44% is 168% above its 1-year average of 15.11%, near the high end of its 1-year range (0.00%–45.33%).
78.41% above its 12-month average of 22.67%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 45.33%.
GROSS MARGIN
40.44%
GROSS MARGIN AVG TTM
22.67%
GROSS MARGIN AVG 3Y
N/A
GROSS MARGIN AVG 5Y
N/A
GROSS MARGIN AVG 10Y
N/A
GROSS MARGIN AVG 15Y
N/A
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+78.41%
CURRENT VS 3Y AVG
N/A
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.38%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-2.27%
vs the sector median at left
Attovia Therapeutics, Inc.
Market Cap
$765.29M
Gross Margin
40.44%
TTM Avg
22.67%
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$764.31M
Gross Margin
65.99%
TTM Avg
63.07%
3Y Avg
62.20%
5Y Avg
62.16%
Market Cap
$775.04M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$778.00M
Gross Margin
34.32%
TTM Avg
34.39%
3Y Avg
32.85%
5Y Avg
32.95%
Market Cap
$778.19M
Gross Margin
98.85%
TTM Avg
98.73%
3Y Avg
-10570.46%
5Y Avg
-10093.61%
Market Cap
$780.95M
Gross Margin
10.37%
TTM Avg
19.20%
3Y Avg
18.44%
5Y Avg
17.81%
Market Cap
$779.45M
Gross Margin
97.42%
TTM Avg
97.90%
3Y Avg
98.95%
5Y Avg
-3197.94%
Market Cap
$738.45M
Gross Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$787.11M
Gross Margin
94.30%
TTM Avg
95.84%
3Y Avg
95.72%
5Y Avg
72.44%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $765.29M | 40.44% | 22.67% | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $764.31M | 65.99% | 63.07% | 62.20% | 62.16% |
| Sana Biotechnology, Inc. (SANA)vs › | $775.04M | 0.00% | 0.00% | 0.00% | 0.00% |
| Varex Imaging Corporation (VREX)vs › | $778.00M | 34.32% | 34.39% | 32.85% | 32.95% |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $778.19M | 98.85% | 98.73% | -10570.46% | -10093.61% |
| AdaptHealth Corp. (AHCO)vs › | $780.95M | 10.37% | 19.20% | 18.44% | 17.81% |
| Geron Corporation (GERN)vs › | $779.45M | 97.42% | 97.90% | 98.95% | -3197.94% |
| Design Therapeutics, Inc. (DSGN)vs › | $738.45M | 0.00% | 0.00% | 0.00% | 0.00% |
| Gyre Therapeutics, Inc. (GYRE)vs › | $787.11M | 94.30% | 95.84% | 95.72% | 72.44% |
| Apnimed, Inc. (APMD)vs › | $737.53M | N/A | N/A | N/A | N/A |
Gross Margin
40.4%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 45.33% |
| 2026-03-31 | 0.00% |
| 2025-03-31 | 0.00% |
